India has stepped up regulatory oversight of GLP-1-based weight loss drugs following a sharp rise in their availability across pharmacies, online platforms and wellness clinics.
The move comes as multiple generic versions enter the domestic market after expiry of the patent on 20 March, increasing access but also raising concerns over misuse and unsafe consumption.
According to a Ministry of Health and Family Welfare statement on Tuesday, 24 March, the action comes as with the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics.
The regulator has warned that the use of such drugs without proper medical supervision may lead to serious adverse effects and related health complications.
In a key regulatory step, a comprehensive advisory was issued on 10 March 2026 to all manufacturers, explicitly prohibiting surrogate advertisements and any indirect promotion that could mislead consumers or encourage off-label use of these drugs.
Enforcement activities have also been significantly scaled up in recent weeks.
Authorities conducted audits and inspections at 49 entities, including online pharmacy warehouses, drug wholesalers, retailers, and wellness or slimming clinics across multiple regions.
These inspections focused on identifying violations related to unauthorized sales, improper prescription practices, and misleading marketing. Further, notices have also been sent to defaulting entities.
The ministry reiterated that GLP-1 weight loss drugs are approved in India only under strict prescription conditions, limited to endocrinologists and internal medicine specialists, and for some indications by Cardiologists only.
Emphasising patient safety, the ministry has advised citizens to use such medications only under the guidance of qualified medical practitioners.
The ministry has indicated that regulatory surveillance will continue to be intensified in the coming weeks, with strict action, including licence cancellations, penalties, and prosecution, against non-compliant entities.
Read also : ISRO plans SPADEX-2 and SPADEX-3 missions to advance orbital docking for Gaganyaan and Indian space station
